Merck Chief Executive Kenneth Frazier was dismissed as an individual defendant in a shareholder lawsuit related to the drug Vioxx in 2011. "Merck To Pay $830 Million To Settle Vioxx Shareholder Suit -- Update," published Jan. 15 at 2:19 p.m. ET, incorrectly reported that he remained a defendant in the case in the sixth paragraph.

(END) Dow Jones Newswires

February 10, 2016 13:19 ET (18:19 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.